Deal Snapshot
Gilead Sciences Closes USD 405m Acquisition of UK Biotech MiroBio
Thursday 22 September 2022

US-based biopharmaceutical company Gilead Sciences (NASDAQ: GILD), Inc. has closed the acquisition of UK-based biotechnology company MiroBio Ltd for around USD 405m in cash, the company said.

MiroBio is focused on restoring immune balance with agonists targeting immune inhibitory receptors.

Date Published: 22/09/2022